MDCXW · Insider Trading
Medicus Pharma Ltd. Warrant
Every open-market purchase and sale reported by MDCXW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-04 | Raza Bokhari | Chief Executive Officer | A | +500,000 deriv. | — |
| 2026-06-04 | Carolyn F. Bonner | President and CFO | A | +250,000 deriv. | — |
| 2026-06-04 | Ajay Raju | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Larry Kaiser | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Patrick J Mahaffy | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Edward J. Brennan | Chief Scientific Officer | A | +25,000 deriv. | — |
| 2026-06-04 | William Ashton | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Robert J. Ciaruffoli | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Cathy McMorris Rodgers | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Andrew Alasdair Smith | Chief Operating Officer | A | +200,000 deriv. | — |
| 2026-06-04 | Barry Fishman | Director | A | +50,000 deriv. | — |
| 2026-06-04 | Faisal Mehmud | Chief Medical Officer | A | +250,000 deriv. | — |
| 2026-06-04 | Sara R. May | Director | A | +50,000 deriv. | — |
| 2026-04-01 | Raza Bokhari | Chief Executive Officer | A | +325,000 deriv. | — |
| 2026-04-01 | Carolyn F. Bonner | President and CFO | A | +100,000 deriv. | — |
| 2026-04-01 | Patrick J Mahaffy | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Andrew Alasdair Smith | Chief Operating Officer | A | +50,000 deriv. | — |
| 2026-04-01 | Cathy McMorris Rodgers | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Larry Kaiser | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Robert J. Ciaruffoli | Director | A | +25,000 deriv. | — |
| 2026-04-01 | William Ashton | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Sara R. May | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Ajay Raju | Director | A | +25,000 deriv. | — |
| 2026-04-01 | Faisal Mehmud | Chief Medical Officer | A | +125,000 deriv. | — |
| 2026-04-01 | Edward J. Brennan | Chief Scientific Officer | A | +25,000 deriv. | — |
| 2026-04-01 | Barry Fishman | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Faisal Mehmud | Chief Medical Officer | A | +75,000 deriv. | — |
| 2025-12-18 | Raza Bokhari | Chief Executive Officer | A | +125,000 deriv. | — |
| 2025-12-18 | Ajay Raju | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Sara R. May | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Barry Fishman | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Andrew Alasdair Smith | Chief Operating Officer | A | +50,000 deriv. | — |
| 2025-12-18 | Patrick J Mahaffy | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Edward J. Brennan | Chief Scientific Officer | A | +50,000 deriv. | — |
| 2025-12-18 | William Ashton | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Larry Kaiser | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Carolyn F. Bonner | President and CFO | A | +75,000 deriv. | — |
| 2025-12-18 | Cathy McMorris Rodgers | Director | A | +25,000 deriv. | — |
| 2025-12-18 | Robert J. Ciaruffoli | Director | A | +25,000 deriv. | — |
| 2025-08-14 | James P. Quinlan | Chief Financial Officer | M | +145,000 | +$156.25K |
| 2025-07-24 | Raza Bokhari | Chief Executive Officer | A | +250,000 deriv. | — |
| 2025-07-24 | Barry Fishman | Director | A | +25,000 deriv. | — |
| 2025-07-24 | Larry Kaiser | Director | A | +25,000 deriv. | — |
| 2025-07-24 | James P. Quinlan | Chief Financial Officer | A | +50,000 deriv. | — |
| 2025-07-24 | Carolyn F. Bonner | President | A | +50,000 deriv. | — |
| 2025-07-24 | William Ashton | Director | A | +25,000 deriv. | — |
| 2025-07-24 | Ajay Raju | Director | A | +25,000 deriv. | — |
| 2025-07-24 | Sara R. May | Director | A | +25,000 deriv. | — |
| 2025-07-24 | Robert J. Ciaruffoli | Director | A | +25,000 deriv. | — |
| 2025-07-24 | Faisal Mehmud | Chief Medical Officer | A | +50,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kenneth R. Melani | 10%+ Owner | 3,248,741 | $779.70K |
| James P. Quinlan | Chief Financial Officer | 274,147 | $65.80K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MDCXW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.